Navigation Links
LabCorp(R) and Vanda Pharmaceuticals Collaborate to Offer Genetic Tests
Date:6/5/2008

andidates to be demonstrably safe and effective; Vanda's failure to obtain regulatory approval for its products or to comply with ongoing regulatory requirements; a lack of acceptance of Vanda's product candidates in the marketplace, or a failure to become or remain profitable; Vanda's inability to obtain the capital necessary to fund its research and development activities; Vanda's failure to identify or obtain rights to new product candidates; Vanda's failure to develop or obtain sales, marketing and distribution resources and expertise or to otherwise manage its growth; a loss of any of Vanda's key scientists or management personnel; losses incurred from product liability claims made against Vanda; a loss of rights to develop and commercialize Vanda's products under its license and sublicense agreements and other factors that are described in the "Risk Factors" section (Part II, Item 1A) of Vanda's quarterly report on Form 10-Q for the quarter ended March 31, 2008 (File No. 000-51863). In addition to the risks described above and in Part II, Item 1A of Vanda's quarterly report on Form 10-Q, other unknown or unpredictable factors also could affect Vanda's results. There can be no assurance that the actual results or developments anticipated by Vanda will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Vanda. Therefore, no assurance can be given that the outcomes stated in such forward-looking statements and estimates will be achieved.

All written and verbal forward-looking statements attributable to Vanda or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements contained or referred to herein. Vanda cautions investors not to rely too heavily on the forward-looking statements Vanda makes or that are made on its behalf. The information in this release is provided only as of the date of this release, and Vanda undertakes no obligation, and specific
'/>"/>

SOURCE Vanda Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results
2. Vanda Pharmaceuticals to Present at the Bank of America 2008 Healthcare Conference
3. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
4. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
7. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
8. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
9. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
10. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
11. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2015)... 30, 2015 Oxford Finance LLC ("Oxford"), a ... sciences and healthcare services companies, today announced the closing ... with Celula, Inc., a diagnostic testing company focused on ... patient care and improved outcomes.  Proceeds of the loan ... the commercialization of its products in the U.S. and ...
(Date:4/30/2015)... April 30, 2015  Asterias Biotherapeutics, Inc. (NYSE MKT: ... of regenerative medicine, today announced that it will release ... 7, 2015 after the close of the U.S. financial ... webcast on Thursday, May 7, 2015 at 4:30 p.m. ... and recent corporate developments. For both "listen-only" ...
(Date:4/30/2015)... SureClinical, a leader in cloud-based health ... joined SureClinical’s executive team as Chief Financial Officer. ... executive with over 25 years in leadership roles ranging ... Ms. Morris joins SureClinical from Marrone Bio Innovations (MBI), ... of MBI from its founding in 2006 until 2011, ...
(Date:4/29/2015)... (TSX-V: BRM) ("Biorem" or "the Company") today announced its results for the ... year-end financial statements and MD&A have been filed on SEDAR ( www.sedar.com ... 2014 , 2013 Revenue 3,968 , 5,121 ... , 1,703 , 2,231 , 5,866 Operating  ... , 4,562 Ebitda* 92 , 418 , ...
Breaking Biology Technology:Oxford Finance Provides $10 Million Debt Financing to Celula 2Asterias Biotherapeutics to Report First Quarter Results on May 7, 2015 2Asterias Biotherapeutics to Report First Quarter Results on May 7, 2015 3Julie I. Morris Joins SureClinical as Chief Financial Officer 2Biorem Reports Results for Fourth Quarter 2014 and Year Ended December 31, 2014 2Biorem Reports Results for Fourth Quarter 2014 and Year Ended December 31, 2014 3Biorem Reports Results for Fourth Quarter 2014 and Year Ended December 31, 2014 4
... EXTON, Pa., Feb. 28, 2012 ViroPharma Incorporated (Nasdaq: ... fourth quarter and year ended December 31, 2011. ... in annual net product sales, including $251 million in net ... in net sales of Vancocin® (Vancomycin Hydrochloride Capsules, USP); ...
... NOVATO, Calif., Feb. 28, 2012 Ultragenyx Pharmaceutical ... for rare and ultra-rare genetic disorders, today announced ... has granted orphan drug designation for UX003 for ... an extremely rare autosomal recessive lysosomal storage disorder ...
... Verenium Corporation (Nasdaq: VRNM ), a leading ... high-performance enzymes, today announced that it will release ... 5, 2012 at 8:00 a.m. ET. In conjunction with the ... webcast on Monday, March 5 at 8:30 a.m. ET. ...
Cached Biology Technology:ViroPharma Incorporated Reports Fourth Quarter and Full Year 2011 Financial Results 2ViroPharma Incorporated Reports Fourth Quarter and Full Year 2011 Financial Results 3ViroPharma Incorporated Reports Fourth Quarter and Full Year 2011 Financial Results 4ViroPharma Incorporated Reports Fourth Quarter and Full Year 2011 Financial Results 5ViroPharma Incorporated Reports Fourth Quarter and Full Year 2011 Financial Results 6ViroPharma Incorporated Reports Fourth Quarter and Full Year 2011 Financial Results 7ViroPharma Incorporated Reports Fourth Quarter and Full Year 2011 Financial Results 8ViroPharma Incorporated Reports Fourth Quarter and Full Year 2011 Financial Results 9ViroPharma Incorporated Reports Fourth Quarter and Full Year 2011 Financial Results 10ViroPharma Incorporated Reports Fourth Quarter and Full Year 2011 Financial Results 11ViroPharma Incorporated Reports Fourth Quarter and Full Year 2011 Financial Results 12Ultragenyx Granted Orphan Drug Designation for UX003 for the Treatment of Mucopolysaccharidosis Type 7 (MPS 7) 2Ultragenyx Granted Orphan Drug Designation for UX003 for the Treatment of Mucopolysaccharidosis Type 7 (MPS 7) 3Verenium Corporation to Announce Fourth Quarter and Year-End 2011 Financial Results 2Verenium Corporation to Announce Fourth Quarter and Year-End 2011 Financial Results 3
(Date:3/30/2015)... , Mar. 26, 2015 Research and Markets ... of the "Global Gesture Recognition Market in Automotive ... The analysts forecast the Global Gesture Recognition market in ... over the period 2013-2018. Gesture recognition is ... to different gestures of an individual. Gesture recognition technology ...
(Date:3/24/2015)... DUBLIN , Mar. 24, 2015 Research and Markets ... "Face and Voice Biometrics - Global Strategic Business Report" report ... for Face and Voice Biometrics in US$ Thousands by the following ... analytics for the US, Canada , ... , Middle East & ...
(Date:3/23/2015)... -- SoundView Technology Group issues a new research update following ... smart wallet. SoundView was one of the selected user groups to ... Wocket in multiple scenarios and outlets. Soundview ... making both debit and credit card payments.  ... company meets their plans in 2015, it would push our ...
Breaking Biology News(10 mins):Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 2Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 3Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 4Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 5Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 6Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 3Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 4
... of Appeals has overturned an August 2010 ban on federal ... broader exploration of how stem cells function and how they ... incurable diseases. The ruling has been welcomed by the ... and by the nation,s top researchers in the field, including ...
... 27, 2011 According to the Centers for Disease Control ... more likely to die from diabetes than someone living in ... parts of the United States. Now, a group of seven ... change those health disparities and improve health through the creation ...
... A gene therapy approach using a protein called ... of age-related macular degeneration (AMD), according to a new ... of Medicine. Led by senior author Rajendra Kumar-Singh, PhD, ... delivered by a gene therapy approach significantly reduced the ...
Cached Biology News:US Appeals Court opens federal funding for stem cell research 2Network created to address obesity, chronic health issues in Appalachian region 2Network created to address obesity, chronic health issues in Appalachian region 3Gene therapy shows promise against age-related macular degeneration 2
6X DNA Gel Loading Buffer is intended for gel electrophoresis of DNA fragments or PCR products....
Xanthine Oxidase (Bovine Buttermilk). Monospecific by IEP. Some cross reactivity with Xanthine Oxidase of other species and tissues may occur....
...
Rabbit polyclonal to XTP4 ( Abpromise for all tested applications). entrezGeneID: 84299 SwissProtID: Q9BRT3...
Biology Products: